WO2023144625A3 - Enhanced hace2-based neutralizing agents against sars-cov-2 infection - Google Patents

Enhanced hace2-based neutralizing agents against sars-cov-2 infection Download PDF

Info

Publication number
WO2023144625A3
WO2023144625A3 PCT/IB2023/000029 IB2023000029W WO2023144625A3 WO 2023144625 A3 WO2023144625 A3 WO 2023144625A3 IB 2023000029 W IB2023000029 W IB 2023000029W WO 2023144625 A3 WO2023144625 A3 WO 2023144625A3
Authority
WO
WIPO (PCT)
Prior art keywords
hace2
proteins
cov
mutant
infection
Prior art date
Application number
PCT/IB2023/000029
Other languages
French (fr)
Other versions
WO2023144625A2 (en
Inventor
Bo Feng
Jingyi Wang
Jiangchuan LI
Original Assignee
The Chinese University Of Hong Kong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chinese University Of Hong Kong filed Critical The Chinese University Of Hong Kong
Publication of WO2023144625A2 publication Critical patent/WO2023144625A2/en
Publication of WO2023144625A3 publication Critical patent/WO2023144625A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided are mutant hACE2 proteins, including at least one mutant hACE2 protein or a combination of at least two different mutant hACE2 proteins, in which one possesses enhanced virus binding features but has no enzymatic activities, and the other one preserves hACE2 enzymatic function as the peptidase to regulate homeostasis but loses the binding activity to viral spike proteins, specifically SARS-CoV-2 spike proteins. The mutant hACE2 proteins can be used in methods to treat viral infections, particularly SARS-CoV-2 infections. The combination of these two mutant hACE2 proteins can provide potent neutralizing agents against SARS-CoV-2 infection with no risk of adversely interfering with body homeostasis of the subject.
PCT/IB2023/000029 2022-01-27 2023-01-27 Enhanced hace2-based neutralizing agents against sars-cov-2 infection WO2023144625A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263303973P 2022-01-27 2022-01-27
US63/303,973 2022-01-27

Publications (2)

Publication Number Publication Date
WO2023144625A2 WO2023144625A2 (en) 2023-08-03
WO2023144625A3 true WO2023144625A3 (en) 2023-09-21

Family

ID=87470845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/000029 WO2023144625A2 (en) 2022-01-27 2023-01-27 Enhanced hace2-based neutralizing agents against sars-cov-2 infection

Country Status (1)

Country Link
WO (1) WO2023144625A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311822A1 (en) * 2002-06-19 2010-12-09 University Health Network ACE2 Activation For Treatment Of Heart, Lung and Kidney Disease and Hypertension
CN112794918A (en) * 2021-02-22 2021-05-14 中国科学院微生物研究所 Human ACE2 modified protein and ACE2-hFc antibody protein for novel coronavirus
CN113527510A (en) * 2020-04-22 2021-10-22 上海交通大学 Fusion protein molecule and preparation method and application thereof
WO2022010938A2 (en) * 2020-07-06 2022-01-13 Avirmax, Inc. Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
CA3181996A1 (en) * 2020-07-14 2022-01-20 Longxing CAO Sars-cov-2 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311822A1 (en) * 2002-06-19 2010-12-09 University Health Network ACE2 Activation For Treatment Of Heart, Lung and Kidney Disease and Hypertension
CN113527510A (en) * 2020-04-22 2021-10-22 上海交通大学 Fusion protein molecule and preparation method and application thereof
WO2022010938A2 (en) * 2020-07-06 2022-01-13 Avirmax, Inc. Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
CA3181996A1 (en) * 2020-07-14 2022-01-20 Longxing CAO Sars-cov-2 inhibitors
CN112794918A (en) * 2021-02-22 2021-05-14 中国科学院微生物研究所 Human ACE2 modified protein and ACE2-hFc antibody protein for novel coronavirus

Also Published As

Publication number Publication date
WO2023144625A2 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
EP4257600A3 (en) Antibodies that target hiv gp120 and methods of use
WO2022167816A3 (en) Antibodies
TW200640482A (en) Variant forms of urate oxidase and use thereof
ATE490778T1 (en) USE OF ÄD-MEALAÜ3-ÄETVALÜ4-CICLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION
TW200716751A (en) A variant form of urate oxidase and use thereof
EP4375382A3 (en) Bacterial strains having fungicidal activity, compositions comprising same and use thereof
WO2007024628A3 (en) Ply-gbs mutant lysins
MX2020007049A (en) Peptides having protease activity for use in the treatment or prevention of coronavirus infection.
WO2008118849A3 (en) Hiv-1 protease inhibitors
WO2020132661A3 (en) Inhibitors of fibroblast activation protein
WO2021174107A3 (en) Soluble ace2 variants and uses therefor
WO2017151860A8 (en) Human kynureninase enzyme variants having improved pharmacological properties
MX2020010932A (en) Human kynureninase enzymes and uses thereof.
WO2020252441A3 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
MX2023004933A (en) Ace2 fusion proteins and uses thereof.
MX2022014034A (en) Methods of treating covid-19 using bardoxolone methyl or analogs thereof.
MX2022006109A (en) 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors.
TN2020000157A1 (en) Binding molecule having neutralizing activity against middle east respiratory syndrome coronavirus
WO2021216876A3 (en) Antibodies to coronavirus spike protein and methods of use thereof
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
WO2023144625A3 (en) Enhanced hace2-based neutralizing agents against sars-cov-2 infection
WO2007002172A3 (en) Hiv-1 protease inhibitors
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2004029201A3 (en) Peptide derivative fusion inhibitors of hiv infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23746537

Country of ref document: EP

Kind code of ref document: A2